A61K - Preparations for medical, dental, or toilet purposes

More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)

Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
12/2002
12/05/2002	CA2448643A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug
12/05/2002	CA2448637A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002	CA2448627A1 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
12/04/2002	EP1261359A2 An improved herbal composition having antiallergic properties and a process for the preparation thereof
12/04/2002	EP1261316A2 Improvements in or relating to the delivery of oral drugs
12/04/2002	EP1097139B1 Quinoline derivatives
12/04/2002	EP1073417B1 Pharmaceutical aerosol formulation
12/04/2002	EP1005342B1 Pharmaceutical compositions of tizoxanide and nitazoxanide
12/04/2002	EP0851752B1 Hand cleanser
12/03/2002	US6489478 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
12/03/2002	US6489330 Or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of such as famciclovir; prophylactic treatment for kaposi's sarcoma or aids related disease
12/03/2002	US6489296 Treatment of hypercoagulable states or acquired protein c deficiency with activated protein c, a highly selective therapeutic agent with a low potential for causing bleeding complications
12/03/2002	CA2129491C Hair coloring composition
12/03/2002	CA2092914C Synergism of tnf and il-4
11/2002
11/28/2002	WO2002094300A1 Herbal compositions for the treatment of mucosal lesions
11/28/2002	WO2002094185A2 Conjugates and compositions for cellular delivery
11/28/2002	US20020177596 2,3,4,4a,5,6-hexahydro-1H-pyrazino(1,2-a)quinoxaline derivatives; treating depression, schizophrenia; (5-hydroxytryptamine=5HT) 5HT2a antagonist or a 5HT2c agonist
11/28/2002	US20020176935 Microprecipitation method for preparing submicron suspensions
11/28/2002	US20020176889 And an excipient wherein the pH is within the range of 5.5-7.0; stability; dosage forms
11/28/2002	US20020176868 Isolation and characterization of the csa operon (ETEC-CS4 pili) and methods of using same
11/28/2002	CA2447180A1 Herbal compositions for the treatment of mucosal lesions
11/28/2002	CA2447161A1 Conjugates and compositions for cellular delivery
11/27/2002	EP1260504A1 Process for the preparation of antihistaminic 4-diphenylmethyl piperidine derivatives
11/27/2002	EP1260222A1 Butenyl-substituted taxanes and composition
11/27/2002	CN1382118A Biocyclic amino acids aspharmaceutical agents
11/27/2002	CN1382061A Pharmaceutical compositions for oral and topical administration
11/27/2002	CN1094755C Controlled release agent containing reamine benzene ring alcohol or it salt
11/26/2002	WO2001093808A1 Ceramic material for dental applications and a method for the production thereof
11/26/2002	US6486182 Mutual prodrugs of amlodipine and atorvastatin
11/26/2002	US6486144 Method of treatment of liver tumors and pharmaceutical compositions for use therein
11/26/2002	US6486137 Oligosaccharide mixtures having antithrombotic activity
11/26/2002	US6486106 Composition
11/26/2002	CA2410448A1 Ceramic material for dental applications and a method for the production thereof
11/26/2002	CA2083377C Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna
11/26/2002	CA2060330C Compositions and method for soft tissue tumors
11/21/2002	WO2002092597A1 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.0?2,11.04.9¿)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002092089A1 Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002091995A2 Method to induce neovascular formation and tissue regeneration
11/21/2002	WO2002055098A3 Latency associated peptide for providing latency to pharmaceutically active proteins
11/21/2002	US20020173467 Peptide in biopolymer; oil in water emulsion
11/21/2002	US20020172673 Method for down-regulating IgE
11/21/2002	US20020172643 For use in diagnostic ultrasonic imaging
11/21/2002	CA2447343A1 Method to induce neovascular formation and tissue regeneration
11/21/2002	CA2446988A1 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/20/2002	EP1258246A2 Controlled release oxycodone compositions
11/20/2002	EP1257584A2 Humanized antibodies that sequester amyloid beta peptide
11/20/2002	EP1257282A1 Pancreatic stem cells and their use in transplantation
11/20/2002	EP0547151B1 Treatment process for promoting weight loss employing a substituted delta 5-androstene
11/20/2002	CN1380883A Novel derivatives and analogues of galanthamin
11/20/2002	CN1380882A C10 ester substituted taxanes as antitumor agents
11/20/2002	CN1094361C Composition comprising propolis and essential oil
11/19/2002	US6482990 Prostaglandin E analogues
11/19/2002	US6482442 Substance mixture for topical application comprising olive oil and honey
11/19/2002	US6482421 Pharmaceuticals, dietary supplements and cosmetic compositions, and the use of certain mixtures for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation, hypersensitivity reactions or pain
11/19/2002	US6482417 Stable pharmaceutical formulation comprising torsemide modification II
11/19/2002	CA2223172C Methods and compositions for use against dental calculus in domestic animals
11/19/2002	CA2092821C Plant-based medicaments for increasing the tone and modulating the tone of the smooth muscular organs
11/19/2002	CA2066134C Complexes of polyadenylic acid with polyuridylic acid
11/19/2002	CA2050970C Pharmaceutical compositions containing furan derivatives
11/14/2002	US20020169172 Phenyl or naphthyl-pyrazine compounds useful in the treatment of central nervous system diseases
11/14/2002	US20020169170 Arylpiperazines having activity at the serotonin 1A receptor
11/14/2002	US20020169105 Use of active enamel substances as wound healing, anti-bacterial and/or anti-inflammatory agents
11/14/2002	US20020168427 Plant extract
11/14/2002	US20020168426 Viricides, bactericides
11/14/2002	US20020168402 Microprecipitation method for preparing submicron suspensions
11/14/2002	US20020168329 For reducing or inhibiting oiliness and greasiness comprising 5-25% by wt C12-C20 fatty acid, 0.1%-10% anionic, nonionic, cationic or amphoteric surfactants, 0.01-10% niacinamide, 0.01% -10% C11-C30 alkyl or alkenyl ester of salicylic acid
11/13/2002	EP1255751A2 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors
11/13/2002	EP1255547A1 Controlled-release compositions containing opioid agonist and antagonist
11/13/2002	EP1113811B1 Chemokine receptor antagonist and cyclosporin in combined therapy
11/13/2002	EP1112272B1 Muscarinic agonists and antagonists
11/13/2002	CN1379775A Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
11/13/2002	CN1379768A Improved aqueous solubility pharmaceutical formulations
11/12/2002	US6479663 Intermediates useful for the preparation of antihistaminic piperidine derivatives
11/12/2002	US6479496 Treating a human patient suffering from variant and exercise-induced angina by administering a sustained release pharmaceutical dosage form including at least 50% by weight ranolazine in no more than two tablets per dose
11/12/2002	US6479483 3,4,6-substituted pyridine derivatives useful for treating depression and pain, resulting from inflammatory conditions, such as migraine, rheumatoid arthritis, asthma and inflamatory bowel disease; nk1 receptor antagonist
11/12/2002	US6479080 Plant extract
11/12/2002	CA2190738C Detergent composition
11/12/2002	CA2107108C Improvements in or relating to contrast agents
11/12/2002	CA2092435C Uracil reductase inactivators
11/12/2002	CA2090920C Opacifier for water-based compositions
11/07/2002	WO2002088159A1 Pharmaceutically active uridine esters
11/07/2002	WO2002088094A1 2-iminoimidazole derivatives (1)
11/07/2002	WO2002088092A1 2-iminoimidazole derivative (2)
11/07/2002	WO2002067889A3 Skin composition for reducing skin oils and grease
11/07/2002	US20020165257 For patients exhibiting resistance to oncology and chemotherapy with taxanes; antiproliferative agents
11/07/2002	US20020164680 ErbB4 receptor-specific neuregulin related ligands and uses therefor
11/07/2002	US20020164384 Aquatic animal treatment method and composition containing pimenta extract
11/07/2002	CA2594883A1 Pharmaceutically active uridine esters
11/07/2002	CA2445861A1 Pharmaceutically active uridine esters
11/06/2002	EP0844865B1 Cosmetic gel composition having reduced skin irritation
11/06/2002	EP0781280B1 Derivatives of benzopyran and of benzothiopyran, their preparation and their use as agonists of dopaminergic receptors
11/06/2002	CN1378547A 5-(2-substituted-5-heterocyclylsulphenylpyrid-3-yl)-dihydropyrazolo [4,3-d] pyrimidin 7-ones as phosphodiesterase inhibitors
11/06/2002	CN1377881A Intermediate for preparing cascade polymeric ligand and contrast medium
11/06/2002	CN1093859C Novel indole-2,3-dione-3-oxime derivatives
11/06/2002	CN1093755C Topical composition for inhibiting hair growth
11/05/2002	US6476059 Use of polycyclic 2-aminothiazole systems for the treatment of obesity
11/05/2002	US6476042 Combination therapy for the treatment of migraine
11/05/2002	US6476040 Processes and intermediates for preparing anti-cancer compounds
11/05/2002	US6475499 Composition for washing keratin materials, based on weakly ethoxylated sorbitan ester
10/2002
10/31/2002	WO2002085860A1 Pyrazole derivatives for treating hiv

1 ... 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 ... 295